SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Read more about SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat SIGA Announces Health Canada Regulatory Approval of Oral TPOXX® Read more about SIGA Announces Health Canada Regulatory Approval of Oral TPOXX® European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Read more about European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Read more about SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Read more about SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021 Read more about SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021 Read more about SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021 SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic Read more about SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last » Subscribe to
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Read more about SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX® Read more about SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Read more about European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Read more about SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Read more about SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021 Read more about SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021 Read more about SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021
SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic Read more about SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic